These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11598492)

  • 1. Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition.
    de La Fuente-Fernández R; Lim AS; Sossi V; Holden JE; Calne DB; Ruth TJ; Stoessl AJ
    J Cereb Blood Flow Metab; 2001 Oct; 21(10):1151-9. PubMed ID: 11598492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
    Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
    Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
    Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
    Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
    Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous dopamine release after pharmacological challenges in Parkinson's disease.
    Piccini P; Pavese N; Brooks DJ
    Ann Neurol; 2003 May; 53(5):647-53. PubMed ID: 12730999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine release in human ventral striatum and expectation of reward.
    de la Fuente-Fernández R; Phillips AG; Zamburlini M; Sossi V; Calne DB; Ruth TJ; Stoessl AJ
    Behav Brain Res; 2002 Nov; 136(2):359-63. PubMed ID: 12429397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study.
    Ouchi Y; Yoshikawa E; Futatsubashi M; Okada H; Torizuka T; Sakamoto M
    J Cereb Blood Flow Metab; 2002 Jun; 22(6):746-52. PubMed ID: 12045673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus.
    Ouchi Y; Nakayama T; Kanno T; Yoshikawa E; Shinke T; Torizuka T
    J Cereb Blood Flow Metab; 2007 Apr; 27(4):803-10. PubMed ID: 16926840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of competition between endogenous dopamine and [11C]raclopride binding in in vitro brain slices using a dynamic autoradiography technique.
    Sasaki T; Ishiwata K; Murata T; Senda M
    Synapse; 2002 Apr; 44(1):42-50. PubMed ID: 11842445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain.
    Ginovart N; Farde L; Halldin C; Swahn CG
    Synapse; 1997 Apr; 25(4):321-5. PubMed ID: 9097390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
    Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
    J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.